These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2081787)

  • 1. The use of monoclonal antibodies for treatment of autoimmune disease.
    Steinman L
    J Clin Immunol; 1990 Nov; 10(6 Suppl):30S-38S; discussion 38S-39S. PubMed ID: 2081787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of antigen-specific therapies for autoimmune disease.
    Steinman L
    Mol Biol Med; 1990 Aug; 7(4):333-9. PubMed ID: 2233245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen-Ia complex.
    Aharoni R; Teitelbaum D; Arnon R; Puri J
    Nature; 1991 May; 351(6322):147-50. PubMed ID: 1709449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4 antibody therapy in systemic lupus erythematosus.
    Wofsy D; Carteron NL
    Semin Immunol; 1990 Nov; 2(6):419-25. PubMed ID: 2104279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular approaches toward a therapy for multiple sclerosis.
    Steinman L
    Riv Neurol; 1987; 57(3):173-4. PubMed ID: 2960007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of a germline, IL-17-neutralizing antibody in murine models of autoimmune inflammatory disease.
    Dallenbach K; Maurer P; Röhn T; Zabel F; Kopf M; Bachmann MF
    Eur J Immunol; 2015 Apr; 45(4):1238-47. PubMed ID: 25545966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The trimolecular complex as a target for specific immunotherapy in experimental autoimmune encephalomyelitis--applications for multiple sclerosis and other human autoimmune disease].
    Miller A; Weiner HL; Abramsky O
    Harefuah; 1992 Aug; 123(3-4):110-5. PubMed ID: 1516860
    [No Abstract]   [Full Text] [Related]  

  • 8. Tolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis: implications for immunotherapy of human autoimmune diseases.
    Miller A; Hafler DA; Weiner HL
    FASEB J; 1991 Aug; 5(11):2560-6. PubMed ID: 1868980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell receptors in autoimmune disease as targets for immune intervention.
    Acha-Orbea H; Steinman L; McDevitt HO
    Genome; 1989; 31(2):656-61. PubMed ID: 2483695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of autoimmune disease by oral tolerance to autoantigens.
    Whitacre CC; Gienapp IE; Meyer A; Cox KL; Javed N
    Clin Immunol Immunopathol; 1996 Sep; 80(3 Pt 2):S31-9. PubMed ID: 8811061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal anti-Ia antibody therapy in animal models of autoimmune disease.
    McDevitt HO; Perry R; Steinman LA
    Ciba Found Symp; 1987; 129():184-93. PubMed ID: 3315501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful prevention and treatment of autoimmune encephalomyelitis by short-term administration of anti-T-cell receptor alpha beta antibody.
    Matsumoto Y; Tsuchida M; Hanawa H; Abo T
    Immunology; 1994 Jan; 81(1):1-7. PubMed ID: 7510661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A synthetic peptide from the third hypervariable region of major histocompatibility complex class II beta chain as a vaccine for treatment of experimental autoimmune encephalomyelitis.
    Topham DJ; Nag B; Arimilli S; Sriram S
    Proc Natl Acad Sci U S A; 1994 Aug; 91(17):8005-9. PubMed ID: 8058747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and treatment of murine experimental allergic encephalomyelitis with T cell receptor V beta-specific antibodies.
    Zaller DM; Osman G; Kanagawa O; Hood L
    J Exp Med; 1990 Jun; 171(6):1943-55. PubMed ID: 1693655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunopathogenic mechanisms in experimental allergic encephalomyelitis.
    Kálmán B; Lublin FD
    Curr Opin Neurol Neurosurg; 1993 Apr; 6(2):182-8. PubMed ID: 7683223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of clinical experimental allergic encephalomyelitis in the rat using fragments and combinations of monoclonal antibodies.
    Brostoff SW; White TM; Powers JM
    J Neuroimmunol; 1988 Jan; 17(2):167-73. PubMed ID: 3257218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention.
    Acha-Orbea H; Mitchell DJ; Timmermann L; Wraith DC; Tausch GS; Waldor MK; Zamvil SS; McDevitt HO; Steinman L
    Cell; 1988 Jul; 54(2):263-73. PubMed ID: 2455603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis.
    Theien BE; Vanderlugt CL; Eagar TN; Nickerson-Nutter C; Nazareno R; Kuchroo VK; Miller SD
    J Clin Invest; 2001 Apr; 107(8):995-1006. PubMed ID: 11306603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibody therapy in rheumatic disease.
    Pitzalis C; Choy E; Kingsley G
    Presse Med; 1994 Mar; 23(11):532-9. PubMed ID: 8022742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New approaches to the regulation of autoimmune disease].
    Kotake S; Matsuda H
    Nippon Ganka Gakkai Zasshi; 1994 Feb; 98(2):121-9. PubMed ID: 8109455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.